

Ikpot (NHLBI), Denis O. Sviridov (NHLBI), David O. Osei-Hwedieh (NHLBI), Scott Turner (KineMed)

*Publication:* Osei-Hwedieh DO, et al. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. *Pharmacol Ther.* 2011 Apr;130(1):83–91. [PMID 21172387]

*Intellectual Property:* HHS Reference No. E–126–2011/0—US Application No. 61/480,986 filed 29 April 2011; PCT Application No. PCT/US1235870 filed 30 April 2012

*Licensing Contact:* Lauren Nguyen-Antczak, Ph.D., J.D.; 301–435–4074; [lauren.nguyen-antczak@nih.gov](mailto:lauren.nguyen-antczak@nih.gov)

*Collaborative Research Opportunity:* The NHLBI Lipoprotein Metabolism Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Hydrocarbon-stapled Apolipoprotein Peptide Mimetics for the Treatment of Cardiovascular Diseases and Inflammation. For collaboration opportunities, please contact Denise Crooks, Ph.D. at [crooksd@nhlbi.nih.gov](mailto:crooksd@nhlbi.nih.gov).

#### Parvovirus B19 Vaccine

*Description of Technology:* Parvovirus B19 (B19V) infection causes fifth disease, a disease characterized by rashes to the face and other parts of the body that primarily affects children. However, adults can also develop fifth disease and it can lead to more severe conditions. Patients that are immunocompromised, such as those who are HIV infected, organ transplant recipients, and cancer patients, can be particularly susceptible to more severe outcomes from B19V infection. Infection can also cause anemia and in pregnant women, it can lead to hydrops fetalis.

The subject technologies are expression vectors for the production of B19V VP1 and VP2 capsid proteins. Co-expression of the two proteins produce empty virus-like particles (VLPs) that can be used to develop a vaccine against parvovirus B19 and a packaging system for infectious B19V virus. Different expression vectors have been developed and optimized for expression in insect cells and more recently in mammalian cell lines such as 293, Cos7, HeLa cells and 293T cells.

*Potential Commercial Applications:* Vaccine against parvovirus B19V.

*Competitive Advantages:* There is currently no B19V vaccine on the market.

*Development Stage:*

- Early-stage
- Pre-clinical
- Clinical

- In vitro data available
  - In vivo data available (animal)
  - In vivo data available (human)
- Inventors:* Neal S. Young, Takashi Shimada, Sachiko Kajigaya, Ning Zhi (NHLBI)

*Publications:*

1. Bernstein DI, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. *Vaccine.* 2011 Oct 6;29(43):7357–63. [PMID 21807052]

2. Zhi N, et al. Codon optimization of human parvovirus B19 capsid genes greatly increases their expression in nonpermissive cells. *J Virol.* 2010 Dec;84(24):13059–62. [PMID 20943969]

*Intellectual Property:*

- HHS Reference No. E–286–1988/2—U.S. Patent No. 5,916,563 issued 29 Jun 1999

- HHS Reference No. E–286–1988/1—U.S. Patent No. 6,001,371 issued 14 Dec 1999; U.S. Patent No. 6,132,732 issued 17 Oct 2000

- HHS Reference No. E–266–2000/0—U.S. Patent No. 6,558,676 issued 06 May 2003

- HHS Reference No. E–011–2010/0—International PCT Appl. No. PCT/US2011/024199 with national stage filings in the U.S. and Europe

*Licensing Contact:* Kevin W. Chang, Ph.D.; 301–435–5018; [changke@mail.nih.gov](mailto:changke@mail.nih.gov)

*Collaborative Research Opportunity:* The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the technology for producing Parvovirus B19 vaccine. For collaboration opportunities, please contact Cecilia Pazman, Ph.D. at [pazmance@mail.nih.gov](mailto:pazmance@mail.nih.gov).

Dated May 2, 2013.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2013–10857 Filed 5–7–13; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; R13 Conference.

*Date:* June 19, 2013.

*Time:* 2:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* D. G. Patel, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 756, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–7682, [pateldg@niddd.nih.gov](mailto:pateldg@niddd.nih.gov).

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; NIDDK nGUDMAP U01 Application Review.

*Date:* July 8, 2013.

*Time:* 9:00 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW., Washington, DC 20015.

*Contact Person:* Xiaodu Guo, Md, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 761, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–4719, [guox@extra.niddd.nih.gov](mailto:guox@extra.niddd.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: May 2, 2013.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013–10856 Filed 5–7–13; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.